Equity Components [Axis]
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Noncontrolling Interest [Member]
Investment, Name [Axis]
Beyond Cancer Ltd [Member]
NeuroNos Ltd [Member]
Ownership [Axis]
Geographical [Axis]
UNITED STATES
AUSTRALIA
BERMUDA
IRELAND
CYPRUS
Income Tax Authority, Name [Axis]
Australian Taxation Office [Member]
Concentration Risk Benchmark [Axis]
Accounts Payable [Member]
Concentration Risk Type [Axis]
Customer Concentration Risk [Member]
Customer [Axis]
One Third Party Vendor [Member]
Two Third-party Vendors [Member]
Two Third-party Vendor [Member]
Financial Instrument [Axis]
Mutual Funds [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Warrant [Member]
Mutual Fund [Member]
Extinguishment of Debt [Axis]
Short-Term Debt [Member]
Measurement Input Type [Axis]
Measurement Input, Expected Term [Member]
Measurement Input, Price Volatility [Member]
Measurement Input, Risk Free Interest Rate [Member]
Long-Lived Asset, Class [Axis]
Clinical and Medical Equipment [Member]
Equipment Deployable as Part of Service Offering [Member]
Computer Equipment [Member]
Furniture and Fixtures [Member]
Leasehold Improvements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Purchase Agreement [Member]
Plan Name [Axis]
2013 Beyond Air Equity Incentive Plan [Member]
Award Type [Axis]
Restricted Stock Units (RSUs) [Member]
2013 BA Plan [Member]
2013 BA EquityIncentivePlan [Member]
2021 Beyond Cancer Ltd Equity Incentive Plan [Member]
2023 Neuro Nos Ltd Equity Incentive Plan [Member]
2026 Pre-funded Warrants [Member]
Restricted Stock [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Legal Entity [Axis]
Beyond Air Inc. [Member]
Income Location [Axis]
Research and Development [Member]
General and Administrative [Member]
NitricGen Agreement [Member]
Avenue Agreement [Member]
March 2024 Raise [Member]
Avenue Extension Agreement [Member]
September 2024 equity offering [Member]
September 2024 Debt Instrument [Member]
September 2025 Inducement [Member]
January, 2026 Equity Offering [Member]
Sub Total [Member]
Pre Funded Warrants Sep 2024 [Member]
Pre Funded Warrants jan 2026 [Member]
Antidilutive Securities [Axis]
Equity Option [Member]
Pre-funded Warrants [Member]
Option Agreement [Member]
NitricGen, Inc [Member]
Award Date [Axis]
Next Milestones [Member]
After Six Months [Member]
Cost of Goods and Service Benchmark [Member]
Supplier Concentration Risk [Member]
Supplier [Member]
Plexus Corp [Member]
Loan Agreement [Member]
Debt Instrument [Axis]
Promissory Note [Member]
Loan and Security Agreement [Member]
Title and Position [Axis]
Director [Member]
Amended Loan Agreement [Member]
Note Purchase Agreement [Member]
Streeterville Capital LLC [Member]
Consolidated Entities [Axis]
Lung Fit PH [Member]
LungFit® PH [Member]
Variable Interest Entities [Member]
Beyond Air [Member]
Segments [Axis]
Business Segment [Member]
Parent Company [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Securities Purchase Agreement [Member]
Sale of Stock [Axis]
Private Placement [Member]
Series A Warrants [Member]
Series B Warrants [Member]
Series A and Series B Warrants [Member]
Institutional Investors [Member]
Participating Officers [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Listing, Par Value Per Share
Statement of Financial Position [Abstract]
ASSETS
Current assets
Cash and cash equivalents
Marketable securities
Restricted cash
Accounts receivable, net
Inventory, net
Other current assets and prepaid expenses
Total current assets
Licensed right to use technology
Right-of-use lease assets
Property and equipment, net
Other assets
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable
Accrued expenses and other current liabilities
Operating lease liability, current portion
Loans payable, current portion
Total current liabilities
Operating lease liability, net
Long-term debt, net
Warrant liability
Total liabilities
Stockholders’ equity
Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding
Common Stock, $0.0001 par value per share: 500,000,000 shares authorized, 743,418 and 589,639 shares issued and outstanding as of June 30, 2026 and March 31, 2026, respectively
Treasury stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income
Total stockholders’ equity attributable to Beyond Air, Inc
Non-controlling interest
Total stockholders’ equity
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues
Cost of revenues
Gross profit
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Other income/(expense):
Dividend/interest income
Interest and finance expense
Change in fair value of warrant liability
Foreign exchange gain/(loss)
Loss on extinguishment of debt
Loss on disposal of fixed assets
Other income
Total other expense
Loss before income taxes
Provision for income taxes
Net loss
Less: net loss attributable to non-controlling interest
Net loss attributable to Beyond Air, Inc.
Other comprehensive income/(loss), net of tax
Foreign currency translation adjustment
Comprehensive loss attributable to Beyond Air, Inc.
Net basic loss per share attributable to Beyond Air, Inc.
Net diluted loss per share attributable to Beyond Air, Inc.
Weighted average number of shares of common stock outstanding - basic
Weighted average number of shares of common stock outstanding - diluted
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Issuance of common stock for warrant exercise
Issuance of common stock upon exercise of warrants, shares
NNOS Issuance of stock
Issuance of common stock - 2025 Reverse Stock Split rounding
Issuance of common stock - 2026 Reverse Stock Split rounding, shares
Issuance of common stock for conversion of debt
Issuance of common stock for conversion of debt, shares
Stock-based compensation
Other comprehensive income
Net loss
Issuance of common stock – At The Market equity offering
Issuance of common stock - At The Market equity offering, shares
Issuance of common stock - 2025 Reverse Stock Split rounding, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation
Amortization of licensed right to use technology
Stock-based compensation
Amortization of debt discount and accretion of debt issuance costs
Change in fair value of warrant liability
Amortization of operating lease assets
Paid in kind interest
Provision for inventory losses
Provision for bad debt
Foreign currency adjustments
Loss on extinguishment of debt
Loss on disposal of fixed assets
Unrealized (gain)/loss on marketable securities
Changes in:
Inventory
Accounts receivable
Other current assets and prepaid expenses
Accounts payable
Accrued expenses
Operating lease liabilities
Net cash used in operating activities
Cash flows from investing activities
Purchase of marketable securities
Proceeds from sale of marketable securities
Security deposits from leases
Purchase of property and equipment
Net cash provided by investing activities
Cash flows from financing activities
Proceeds from issuance of common stock through at the market offerings
Proceeds from NeuroNos investment
Proceeds from long term loan
Payment of loans
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Increase/(decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of non-cash investing and financing activities
Conversion of debt principal balance to equity
Fixed assets included in accounts payable and accrued expenses
Supplemental disclosure of cash flow items:
Interest paid
Income taxes paid
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Trading Arrangements, by Individual [Table]
Trading Arrangement [Axis]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BUSINESS
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES
Property, Plant, and Equipment [Abstract]
PROPERTY AND EQUIPMENT
Equity [Abstract]
STOCKHOLDERS’ EQUITY
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
OTHER CURRENT ASSETS AND PREPAID EXPENSES
Payables and Accruals [Abstract]
ACCRUED EXPENSES
Earnings Per Share [Abstract]
BASIC AND DILUTED NET INCOME (LOSS) PER SHARE OF COMMON STOCK
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Debt Disclosure [Abstract]
LOANS
Lease Revenues
LEASE REVENUES
Segment Reporting [Abstract]
SEGMENTS
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Basis of Presentation
Principles of Consolidation
Use of Estimates
Going Concern, Liquidity and Other Uncertainties
Other Risks and Uncertainties
Revenue Recognition
Fair Value Measurements
Cash and Cash Equivalents, Short-Term Investments and Restricted Cash
Concentration of Credit Risk
Research and Development
Supplier Concentration
Leases
SCHEDULE OF FAIR VALUE ON A RECURRING BASIS
SUMMARY OF SHORT-TERM MARKETABLE SECURITIES WITH UNREALIZED GAINS AND LOSSES
SCHEDULE OF ASSUMPTIONS USED IN VALUING WARRANTS
SCHEDULE OF CHANGES IN FAIR VALUE OF WARRANTS
SCHEDULE OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
SCHEDULE OF PROPERTY AND EQUIPMENT
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF RESTRICTED STOCK AWARDS
SCHEDULE OF OPTION ACTIVITY FOR NEURONOS
SCHEDULE OF FAIR VALUE OF OPTION
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE
SUMMARY OF OUTSTANDING WARRANTS
SCHEDULE OF OTHER CURRENT ASSETS AND PREPAID EXPENSES
SUMMARY OF ACCRUED EXPENSES
SCHEDULE OF POTENTIAL ANTI-DILUTIVE SECURITIES
SCHEDULE OF LONG-TERM DEBT
SCHEDULE OF MATURITY OF FUTURE LEASE PAYMENTS
SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT
OrganizationConsolidationAndPresentationOfFinancialStatementsTable [Table]
Ownership percentage
Reverse stock split
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total assets measured and recorded at fair value
Total liabilities measured and recorded at fair value
Total short-term marketable securities, Fair value
Total short-term marketable securities, Unrealized gains and (losses)
Business Combination [Table]
Business Combination [Line Items]
Expected term warrants
Warrants and rights outstanding, measurement input
Warrants, balance
Change in fair value of warrants
Warrants, balance
Total cash, cash equivalents and restricted cash
Marketable securities:
Total marketable securities
Total cash, cash equivalents, marketable securities and restricted cash
Nature of Operation, Product Information, Concentration of Risk [Table]
Product Information [Line Items]
Non-controlling owners interest
Net cash used in operating activities
Accumulated deficit
Cash equivalents
Cash deposit
Restricted cash
Proceeds from issuance of secured promissory note
Cash FDIC insured amount
Concentration risk benchmark description
Tax Rebate
Concentration percentage
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Property and equipment, gross
Accumulated depreciation
Property and equipment, net
Depreciation and amortization
Unvested Number of Shares, Beginning balance
Weighted Average Grant Date Fair Value, Beginning balance
Number of Shares, Granted
Weighted Average Grant Date Fair Value, Granted
Number of Shares, Vested
Weighted Average Grant Date Fair Value, Vested
Number of Shares, Forfeited
Weighted Average Grant Date Fair Value, Forfeited
Unvested Number of Shares, Ending balance
Weighted Average Grant Date Fair Value, ending balance
Number of Options, Outstanding at beginning of period
Weighted Average Exercise Price - Options, Outstanding at beginning of period
Weighted Average Remaining Contractual Life - Options, Outstanding at end of period
Aggregate Intrinsic Value, Outstanding at beginning of period
Number of Options Outstanding, Granted
Weighted Average Exercise Price - Options, Granted
Number of Options Outstanding, Exercised
Weighted Average Exercise Price - Options, Exercised
Number of Options Outstanding, Forfeited
Weighted Average Exercise Price - Options, Forfeited
Number of Options, Outstanding at ending of period
Weighted Average Exercise Price - Options, Outstanding at ending of period
Aggregate Intrinsic Value, Outstanding at end of period
Number of Options Outstanding, Exercisable
Weighted Average Exercise Price - Options, Exercisable
Weighted Average Remaining Contractual Life - Options, Exercisable
Aggregate Intrinsic Value, Exercisable
Weighted average remaining contractual life - options, outstanding at beginning of period
Number of Options, Granted
Weighted Average Exercise Price of Options, Granted
Number of Options, Exercised
Weighted Average Exercise Price of Options, Exercised
Number of Options, Forfeited
Weighted Average Exercise Price of Options, Forfeited
Weighted Average Remaining Contractual Life of Options, Exercisable
Weighted Average Remaining Contractual Life of Options, Outstanding
Weighted average exercise price - options, forfeited
ScheduleOfFairValueOfOptionTable [Table]
Risk-free interest rate
Expected volatility
Dividend yield
Expected term (in years)
ScheduleOfStockBasedCompensationExpenseTable [Table]
IncomeLocationAxis [Axis]
Total stock-based compensation expense
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of Warrants
Exercise Price
Intrinsic Value
Date of Expiration
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share purchase value
Shares available for resale
Common stock minimum purchase amount
Beneficial ownership limitation percentage
Price per share
Adjustments in additional paid in capital
Stock option shares authorized for issuance
Number of shares available for grant
Vesting period
Share based compensation
Weighted average remaining service period
Expiration period
Unrecognized stock-based compensation expense
Weighted average fair value of options granted
Number of additionl shares reserve for issuance
Unrecognized stock-based compensation expense
Stock issued during the period, shares
Research and development
Prepaid insurance
Prepaid rents and tenant improvement
Value added tax receivable
Deposits to secure manufacturing materials
Demonstration materials
Other
Total other current assets and prepaid expenses
Research and development
Professional fees
Employee salaries and benefits
Accrued severance
Accrued interest
Deferred revenue
Goods received not invoiced
Other
Total accrued expenses and other current liabilities
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Warrants included in calculation of diluted net loss per share
Product Liability Contingency [Table]
Payments for development and milestone payment
Remaining future milestone payments
Sales related milestones payments
Future payments based on certain milestones
Warrants to purchase common stock
Warrants to purchase common stock, value
Outstanding amount under purchase
Deposits
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Principal balance outstanding
Paid in kind interest
Debt discount
Amortization of debt discount
Total
Schedule of Long-Term Debt Instruments [Table]
Principal amount
Interest rate
Percentage of interest payable in cash
Percentage of interest payable in kind
Royalty interest percentage
Warrants to purchase common stock
Warrants exercise price
Advanced financing from related party
Warrants term
Debt instrument term
Interest rate description
Debt instrument, interest rate
Principal in restricted account
Debt instrument, principal repayable
Shares issued of common stock
Debt amount
Lessee, Lease, Description [Table]
Contract term
Lease revenue
Cash
Useful Life
Depreciation expense
2027
2028
2029
2030
Total
Segment Reporting [Table]
Number of repotable segments
Sale of stock shares
Common share par value
Purchase price per share
Retained percentage
Non-controlling owners interest
Segment Reporting [Line Items]
Capital expenditures
Cost of revenues
Research and development
Selling, general, and administrative
Loss from operations
Other non-operating income/(expense)
Net loss before income taxes
Stock-based compensation expense
Cash used in operations
Cash from investing
Cash from financing
Impact of exchange rates
Net change for the period
Cash, cash equivalents and marketable securities
All other assets
Total liabilities
Net assets
Subsequent Event [Table]
Subsequent Event [Line Items]
Number of shares issued
Warrants to purchase of common stock
Exercise price per share
Gross proceeds from issuance of private placement
Net proceeds from issuance of private placement
Placement agent fees
Other offering expenses
Number of shares purchased
Number of shares purchased, value
Maturity date description
Warrant liability.
Reduction in the value of shares issued during the period as a result of a reverse stock split.
Payments to security deposits made on operating leases.
Proceeds from sale of common stock of neuronos.
Proceeds from long term debt.
Debt principal balance converted to equity.
Beyond Cancer Ltd [Member]
NeuroNos Ltd [Member]
Purchase Agreement [Member]
Beneficial ownership limitation percentage.
2013 Beyond Air Equity Incentive Plan [Member]
2013 BA Plan [Member]
Going Concern Liquidity and Other Uncertainties [Policy Text Block]
Cash and cash equivalents and marketable securities.
Other Risks and Uncertainties [Policy Text Block]
2013 BA EquityIncentivePlan [Member]
2021 Beyond Cancer Ltd Equity Incentive Plan [Member]
Schedule Of Change In Fair Value Of Warrants And Derivatives [Table Text Block]
Warrants liability.
Change in fair value of warrants.
Contract Manufacturer [Member]
Tax rebate.
Supplier Concentration [Policy Text Block]
One Third Party Vendor [Member]
Two Third-party Vendors [Member]
Accrued prepaid research and development expenses.
Interest severance current.
2023 Neuro Nos Ltd Equity Incentive Plan [Member]
Goods received not invoiced.
Two Third-party Vendor [Member]
Pre-funded Warrants [Member]
Payments for development and milestone payment.
Option Agreement [Member]
Milestone payments.
Sales related milestones payments.
NitricGen, Inc [Member
NitricGen Agreement [Member]
Payment for milestone method revenue recognized.
Next Milestones [Member]
After Six Months [Member]
Supplier [Member]
Loan Agreement [Member]
Promissory Note [Member]
Paid in kind interest amount.
Amortization of Debt Discount.
Loan and Security Agreement [Member]
Debt instrument interest rate payable in cash percentage.
Debt instrument interest rate payable in kind percentage.
Royalty interest percentage.
Amended Loan Agreement [Member]
Beyond Air Inc. [Member]
Note Purchase Agreement [Member]
Retained percentage.
Variable Interest Entities [Member]
Beyond Air [Member]
Business Segment [Member]
Capital expenditures cost.
2026 Pre-funded Warrants [Member]
Avenue Agreement [Member]
March 2024 Raise [Member]
Avenue Extension Agreement [Member]
September 2024 equity offering [Member]
September 2024 Debt Instrument [Member]
September 2025 Inducement [Member]
January, 2026 Equity Offering [Member]
Sub Total [Member]
Pre Funded Warrants Sep 2024 [Member]
Pre Funded Warrants jan 2026 [Member]
Warrants Intrinsic Value.
Warrants expiration date description.
Prepaid research and development.
Number of reportable segments disclosed by definition flag.
Income location [Axis]
Research and Development [Member]
General and Administrative [Member]
Debt instrument of restricted account.
Operating Leases [Text Block]
Operating lease income.
Lung Fit PH [Member]
LungFit® PH [Member]
Streeterville Capital LLC [Member]
Mutual Funds [Member]
Clinical and Medical Equipment [Member]
Equipment Deployable as Part of Service Offering [Member]
Plexus Corp [Member]
Securities Purchase Agreement [Member]
Institutional Investors [Member]
Directors and Officers [Member]
Series A and Series B Warrants [Member]
Participating Officers [Member]
The cash inflow associated with the gross amount received from entity's raising of capital via private rather than public placement.
Placement agent fees.
Series A Warrants [Member]
Series B Warrants [Member]
Assets, Current
Assets
Liabilities, Current
Liabilities
Treasury Stock, Value
Equity, Attributable to Parent
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Gross Profit
Operating Expenses
Interest Expense, Nonoperating
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Income Tax Expense (Benefit)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Shares, Outstanding
Gain (Loss), Foreign Currency Transaction, after Tax
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Increase (Decrease) in Inventories
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
Payments to Acquire Marketable Securities
PaymentsToSecurityDepositsMadeOnOperatingLeases
Payments to Acquire Property, Plant, and Equipment
Repayments of Bank Debt
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
WarrantsLiability
Restricted Cash and Cash Equivalent
Restricted Cash
Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
PrepaidResearchAndDevelopment
AccruedResearchAndDevelopmentExpenses
Other Accrued Liabilities, Current
PaidInKindInterestAmount
Debt Instrument, Unamortized Discount
Long-Term Debt, Gross
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Lessee, Operating Lease, Liability, to be Paid
Subsidiary, Ownership Percentage, Parent